HIMS Hims Hers Health Inc
Company Analysis
Latest News
🟢 Hims Hers Health Inc is trading 5.6% up today as shares extend a rebound from Eucalyptus acquisition and dilution concerns
Hims Hers Health Inc is trading 5.6% up at $29.05, extending a sharp multi-day rebound as investors reassess the impact of its $1.15 billion Eucalyptus...
🔴 Hims & Hers Health Inc. falls 4.5% as investors weigh Eucalyptus acquisition and potential dilution
Hims & Hers Health Inc. is trading 4.5% down at $26.27 as investors react to the company's recently completed acquisition of Australian telehealth platform...
Hims & Hers Completes Acquisition of Eucalyptus, Expanding Global Consumer Health Platform
Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, a digital health company, significantly expanding its international footprint and...
Hims & Hers Rallies 17% in a Week on Wall Street Upgrades — But Can a Telehealth Company Really Grow Into a $35 Stock?
Shares of Hims & Hers Health surged 6.8% to $27.94 on June 1, extending a blistering multi-week rally that has lifted the stock roughly 17% in just five...
🟢 Hims Hers Health Inc is trading 6.9% up today as JPMorgan initiates coverage with a $35 target
Hims Hers Health Inc is trading 6.9% up at $27.94 as the stock extends a strong multi-week rally supported by increasingly bullish Wall Street views and growth...
🟢 Hims Hers Health Inc is trading 5.2% up today, extending a multi-week rally on bullish analyst sentiment
Hims Hers Health Inc is trading at $27.51 (up 5.2%) as the stock continues its strong multi-week rally supported by positive analyst coverage and long-term...
🔴 HIMS is trading 3.7% down today on profit-taking and convertible debt dilution risk
HIMS is trading at $24.43 (3.7% down) as investors take profits following a strong multi-day run. • The move appears stock-specific rather than market-driven,...
🔴 HIMS is trading 4.4% down today on profit-taking after a multi-day rally
HIMS is trading at $24.27, down 4.4%, as investors lock in gains following a strong multi-day rally. • The decline comes despite a lack of fresh...
🟢 HIMS is trading 5.4% up today after director David Wells buys $1.1M in stock
HIMS is trading 5.4% up today at $25.14 following a $1.1 million insider share purchase by director David B. Wells. * Wells acquired 48,400 Class A shares...
🟢 HIMS is trading 5.1% up today after director David B. Wells buys $1.1M in stock
HIMS is trading 5.1% up at $25.06 following a significant insider share purchase by director David B. Wells. • Director Wells acquired 48,400 Class A shares...
Hims & Hers Director Buys Shares Worth Over $1.1 Million
Shares of Hims & Hers Health (NYSE:HIMS) rose in after-hours trading on Tuesday. An SEC Form 4 filing revealed the insider purchase. Director David B. Wells...
Hims & Hers faces target cut, following BofA Wegovy growth doubts
BofA Securities lowered the price target for Hims & Hers Health to $25 from $28. The bank expressed concerns regarding the company's ability to meet its 2026...
Hims & Hers pivots to peptides, targeting longevity market after GLP-1 scrutiny
Hims & Hers Health Inc. is expanding into peptides and wellness products, according to a report from The Washington Post. CEO Andrew Dudum plans to enter the...
Hims & Hers Issues $402.5 Million in 0.00% Convertible Senior Notes Due 2032
Hims & Hers Health, Inc. announced the issuance of $402.5 million in aggregate principal amount of 0.00% Convertible Senior Notes due 2032. The total amount...
🟢 HIMS is trading 4% up today on its generic semaglutide launch in Canada
HIMS is trading 4% up today at $23.96 following the launch of its generic semaglutide weight-loss offering in Canada. • The move marks the company's first...
Hims & Hers debuts generic semaglutide in Canada, targeting high treatment costs
Hims & Hers Health is launching a generic version of semaglutide for eligible customers in Canada. This medication contains the active ingredient found in...
Hims & Hers Completes $350 Million Convertible Notes Offering
Hims & Hers Health Inc. completed an upsized private offering of $350 million in convertible senior notes. The notes carry a 0.00% interest rate and mature...
Hims & Hers Prices Upsized $350M Convertible Notes Offering to Fund Expansion and AI
Hims & Hers Health, Inc. announced the pricing of an upsized private offering of $350 million in 0.00% convertible senior notes due 2032. The offering was...
Hims & Hers Upsizes $350 Million Offering, Targets Global Expansion
Hims & Hers Health, Inc. priced an upsized $350 million offering of convertible senior notes. The notes reach maturity in 2032. The company increased the deal...
Hims & Hers Raises Another $300 Million in Convertible Debt — But Can a Company Already Bleeding Cash Afford to Dilute Its Way to Growth?
Shares tumbled 7.8% to $23.09 this morning after Hims & Hers announced a $300 million convertible senior notes offering due 2032 — its second major debt raise...